Can ibogaine kill you?

Yes, in specific circumstances — almost exclusively in the absence of pre-ceremony cardiac screening. Ibogaine prolongs the QT interval throughout the active experience. In someone with pre-existing QT prolongation, this can precipitate ventricular arrhythmia. The pre-ceremony EKG identifies that risk factor before ceremony. Most documented ibogaine-related deaths occurred without adequate cardiac screening — no EKG, or undisclosed medications with QT-prolonging effects, or home use without any medical supervision. In a properly screened programme with an on-site physician and continuous ECG monitoring, the risk profile is materially different.

What is QT prolongation and why does ibogaine cause it?

QT prolongation is an extension of the electrical recovery phase of the heartbeat, visible on a 12-lead EKG as a lengthened QT interval. Ibogaine blocks hERG potassium channels in cardiac tissue — the same mechanism that makes certain antibiotics dangerous in people with cardiac risk factors — producing QT interval prolongation throughout the 12–24 hour active experience. In someone with a QTc already above 450ms (men) or 470ms (women) at baseline, ibogaine can extend the interval into the range associated with torsades de pointes, a ventricular arrhythmia. The EKG identifies the baseline measurement before ceremony.

How is cardiac risk managed during an ibogaine ceremony?

Through three concurrent measures: pre-ceremony EKG identifying any baseline QT prolongation or arrhythmia that would disqualify the candidate; a physician physically present on-site throughout the full 12–24 hour active experience; and continuous cardiac ECG monitoring running throughout the ceremony. If an arrhythmia develops during the experience, it is identified in real time, not discovered afterward. Emergency response capability — equipment and trained personnel — must be on-site. These three components together constitute a programme that manages the cardiac risk. Any programme that omits one of them does not.

Are ibogaine deaths common?

Ibogaine-related deaths have occurred. The rate in properly screened, medically supervised programmes is substantially lower than the rate in unsupervised or unscreened settings. Most documented fatalities involved no pre-ceremony EKG, undisclosed contraindicated medications, home use without medical supervision, or providers without the infrastructure to identify or respond to cardiac events. These are not failures of ibogaine as a compound — they are failures of the screening and monitoring process. The distinction matters. Citing ibogaine mortality statistics without distinguishing between screened and unscreened contexts misrepresents the actual risk in a supervised programme.

Can someone with a history of cardiac conditions ever do ibogaine?

It depends on the specific condition and what the EKG shows. A QTc above 450ms in men or 470ms in women, documented significant arrhythmia, or recent myocardial infarction are absolute contraindications. A cardiac history that produced those findings disqualifies the candidate. A cardiac history that does not produce those findings on a current EKG requires additional cardiovascular assessment before candidacy can be established, but does not automatically disqualify. The specific condition, current EKG readings, and the judgement of the reviewing physician determine candidacy. There is no general rule for cardiac histories other than: the EKG determines whether the current cardiac status is compatible with ceremony.

What should I do if I am on antidepressants and want to do ibogaine?

Contact a provider and discuss the medication before booking anything. SSRIs and SNRIs are absolute contraindications for ibogaine ceremony — the mechanism of concern is serotonin syndrome, which can be fatal. The medication must be fully tapered and cleared before ceremony. The taper must be supervised by the prescribing physician — do not stop psychiatric medication on your own. Fluoxetine has a significantly longer half-life than other SSRIs and may require 4–6 weeks of clearance after the final dose. The taper and clearance window are established between the prescribing physician and the ibogaine provider. No ceremony date is set before this process is complete.

Who is absolutely not appropriate for ibogaine under any circumstances?

People with QT prolongation or significant cardiac arrhythmia on EKG; recent myocardial infarction; severe liver or kidney disease; active psychosis or schizophrenia-spectrum disorder; a first-degree family member with schizophrenia; current lithium use; and pregnancy — these are absolute contraindications. They are not thresholds to weigh against perceived benefit. They are conditions under which ibogaine ceremony cannot be administered safely at any provider, regardless of how the programme is described. Some other contraindications — SSRIs, methadone — are temporary: they require specific preparation protocols before candidacy can be established.

What does safe ibogaine use actually require?

Pre-ceremony EKG and cardiovascular assessment; blood panel covering liver enzymes, kidney function, and CBC; complete medication review; a physician physically present on-site throughout the 12–24 hour active experience; continuous cardiac ECG monitoring for the full ceremony duration; and emergency response capability on-site. These are the components of a medically supervised ibogaine programme. Any provider who omits any of these is not offering a safe programme regardless of what else they include. The cost at Transcend in Vancouver, BC is $2,000–$5,000 CAD — a range that covers this infrastructure. Providers offering substantially less are not finding efficiencies; they are removing components of the safety structure.

Is Ibogaine Safe? The Cardiac Risk, Screening Protocol, and Honest Answer

Ibogaine is not safe without cardiac screening. That is the honest answer, and it matters for everything that follows.

The medicine prolongs the QT interval — the electrical recovery phase of each heartbeat — throughout the 12–24 hour active experience. In someone with pre-existing QT prolongation, ibogaine can push that interval into the range associated with ventricular arrhythmia. The pre-ceremony EKG identifies that person before they sit down with the medicine, not during it. When you see data suggesting ibogaine is dangerous, the context is almost always: no EKG was done.

With screening in place, the risk profile changes. The contraindicated person is screened out. The person with a clean cardiovascular profile proceeds under physician supervision with continuous cardiac monitoring running for the full duration. The outcomes are not the same as unscreened use. They are not comparable.

Ibogaine prolongs the QT interval via hERG potassium channel blockade throughout the 12–24 hour ceremony. Mandatory pre-ceremony EKG identifies pre-existing QT prolongation before ceremony, not during it. Absolute cardiac contraindications: QTc above 450ms (men) or 470ms (women), significant arrhythmia, recent myocardial infarction. Severe liver disease, active psychosis, SSRIs/SNRIs without completed taper, lithium, methadone without transition protocol, and pregnancy are also absolute contraindications. Iboga ceremony at Transcend in Vancouver, BC costs $2,000–$5,000 CAD and includes an on-site physician and continuous ECG monitoring throughout the active experience.

ECG printout displaying heart rhythm — cardiac screening with EKG is required before every ibogaine ceremony — Photo via Pexels

What the cardiac risk actually is

Ibogaine blocks hERG potassium channels in cardiac tissue — the same channel that certain antibiotics and antifungals affect in people with cardiac risk factors. The result is QT interval prolongation: the electrical recovery phase of each heartbeat takes longer. When the QTc interval extends past a threshold, the conditions for torsades de pointes — a ventricular arrhythmia that can degenerate into ventricular fibrillation — are present. That is what “fatal arrhythmia” refers to in discussions of ibogaine cardiac risk.

This risk is not hypothetical. Ibogaine-related deaths from cardiac causes have occurred. The question is not whether this risk exists — it does — but whether the screening process identifies the people most at risk before ceremony rather than after. The answer, when screening is done properly, is yes.

The QTc interval at baseline is the relevant measurement. A QTc above 450ms in men or above 470ms in women at baseline is a contraindication. Ibogaine adds to that baseline throughout the 12–24 hour active experience. A baseline that is already elevated is a baseline that ibogaine can push into dangerous territory. The pre-ceremony EKG measures that baseline. Providers who do not require an EKG are not measuring it.

Ibogaine is also metabolised hepatically, primarily via the CYP2D6 enzyme. Compromised liver function extends the active duration of ibogaine unpredictably — because the compound is not clearing at the expected rate. Severe liver disease is an absolute contraindication because the metabolic pathway is compromised in a way that creates uncontrolled exposure. A blood panel identifying liver enzyme elevation before ceremony is not optional. It is how you know whether that pathway is intact.

The research on ibogaine's pharmacology is published and peer-reviewed. The 2023 Stanford study in Nature Medicine documented 88% reductions in PTSD symptoms and 87% reductions in depression symptoms at one month in 30 treatment-resistant veterans — conducted with full cardiac monitoring infrastructure. That evidence exists because the protocol included the safety measures that made it possible to conduct safely.

Where ibogaine deaths have occurred — and why

Analysis of documented ibogaine-related fatalities consistently identifies a common set of circumstances. Not uniform — the cases vary — but common enough to identify a pattern:

No pre-ceremony EKG.
Medications that further prolong the QT interval — certain antibiotics, antifungals, some antihistamines — not disclosed or not reviewed.
Home use, unsupervised, without any medical equipment or emergency response capability.
Providers with no medical training, no monitoring equipment, and no protocol for identifying or responding to cardiac events.

The category of “ibogaine is dangerous” deaths is dominated by this subset. The category of “ibogaine was administered with proper screening, physician presence, and continuous ECG monitoring” deaths is materially smaller. These are not the same population. Citing ibogaine mortality statistics without distinguishing between these two contexts is not giving you an accurate picture of the risk you face in a properly screened programme.

This is not an argument that ibogaine is risk-free in supervised settings. There is no compound that is risk-free in any setting. What it is is an argument that the category of risk responsible for most documented deaths is addressable — and that addressing it is what separates a legitimate ibogaine programme from one that is not.

The MAPS ibogaine research programme has been documenting the pharmacology and safety requirements of ibogaine treatment for decades. The consistent finding: pre-ceremony cardiac screening is the single most important safety determinant. This is not a niche position. It is the clinical consensus among everyone who has studied this seriously.

What medical screening involves

The screening required before ibogaine ceremony at a legitimate provider has five components. None are optional. None can be substituted with a self-report form or a phone conversation. They are clinical documentation requirements — because ibogaine has clinical contraindications that require clinical documentation to identify.

For more detail on ibogaine contraindications — the full list, there is a dedicated article. The screening requirements for each:

EKG with QTc assessment. The 12-lead EKG is reviewed for baseline QTc interval and any structural abnormalities. A cardiology read is preferred over a general practitioner read for anyone with any cardiac history. This is the most important piece of pre-ceremony documentation. An EKG can be obtained at any cardiology clinic or most walk-in centres and the results sent to the ibogaine provider remotely. No legitimate provider confirms a ceremony date without reviewing it.
Blood panel: liver enzymes, kidney function, CBC. ALT, AST, and total bilirubin establish whether hepatic metabolism of ibogaine is intact. Kidney function panels establish clearance capacity. Severe liver disease is a permanent contraindication. Elevated enzymes that are improving — common in people who have recently reduced alcohol use — require reassessment at a lower level before candidacy can be established, not a permanent no.
Complete medication review. Every prescription, supplement, and intermittent medication. The review identifies SSRIs, SNRIs, lithium, methadone, and medications with QT-prolonging effects that interact with ibogaine. This list is longer than most people expect. Certain antibiotics, antifungals, and cardiac medications also require review. Incomplete disclosure here means a contraindication is not identified before ceremony.
Full cardiac history. Prior cardiac events, arrhythmia diagnoses, hypertensive history, any cardiac surgery. A recent myocardial infarction is an absolute contraindication. Any arrhythmia history requires additional cardiovascular assessment before the QTc measurement alone is sufficient to establish candidacy.
Psychiatric history. Current diagnoses, past hospitalisations, family history of psychosis or schizophrenia-spectrum disorder. Active psychosis and schizophrenia-spectrum disorders are absolute contraindications. A first-degree family member with schizophrenia is a contraindication even in someone currently without symptoms. Acute psychiatric instability at the time of application is not a reason to proceed urgently — it is a reason to address the instability first.

At Transcend, the screening conversation happens before the ceremony date. The documentation is reviewed before candidacy is confirmed. This sequence is not a bureaucratic preference — it is how the screening functions. Reversing the order, confirming a date before reviewing screening documentation, defeats the purpose entirely.

For more on how ibogaine works pharmacologically, including the receptor systems involved, there is a separate article.

Who is not right for this

Not everyone who applies is an appropriate candidate. Some people contact us after years of trying everything else — SSRIs that blunted rather than resolved, therapy that circled without landing, abstinence programmes that held for months and then did not. By the time they arrive, they have evidence that other approaches are not enough, and they are not naive about the difficulty of what they are attempting.

Some of those people are still not appropriate candidates. The screening conversation that ends in “this is not the right path for you right now” is one of the most important things this work involves. People in crisis who have found a thread of hope do not receive a no easily. Saying it clearly, without softening it, is an act of care — not rejection.

The absolute contraindications for ibogaine ceremony:

QT prolongation or significant cardiac arrhythmia. A QTc above 450ms in men or 470ms in women on the baseline EKG is a disqualifier. Documented arrhythmia history requires additional cardiovascular assessment before any candidacy discussion can proceed. This threshold cannot be argued around.
Recent myocardial infarction. Any recent MI is an absolute contraindication. Full cardiovascular reassessment would be required before any timeline could be discussed.
Severe liver or kidney disease.Severe liver disease is a permanent contraindication. Kidney disease impairs clearance in a way that extends ibogaine's active duration unpredictably. Elevated-but-improving enzyme levels are not the same as severe disease.
Current SSRIs or SNRIs without completed supervised taper. This is the most common temporary contraindication in people who contact us. SSRIs and SNRIs are the most commonly prescribed treatments for the conditions ibogaine is most often sought for — depression, PTSD, anxiety — and they cannot be present at the time of ceremony. The mechanism of concern is serotonin syndrome, which can be fatal. The taper must be completed under physician supervision. Fluoxetine requires 4–6 weeks of clearance after the final dose. This is a temporary disqualifier — it requires preparation, not a permanent no.
Active psychosis or schizophrenia-spectrum disorder. No exception to this rule. The experience amplifies what is present. Entering it in a state of active psychosis does not produce stability.
First-degree family member with schizophrenia.The genetic risk factor is clinically relevant regardless of the applicant's own current psychiatric status.
Methadone without completed transition protocol. Transitioning from methadone to a shorter-acting opioid under physician supervision is required before ibogaine is appropriate. The preparation timeline for this population is longer. It is not a permanent no — but it requires a specific protocol first.
Lithium. Absolute contraindication. No protocol makes it safe. No exception.
Pregnancy. Absolute contraindication.

Acute psychiatric instability — someone in a crisis state at the time of application — is also a disqualifier. Not because this work cannot help with the conditions that produced the crisis, but because ceremony is not the first response to acute instability. The appropriate first response to acute instability is acute stabilisation. That is a different kind of support.

If you are on this list, you should know it before you apply. The screening conversation establishes candidacy. We respond to every application personally within 2–3 business days.

What safety looks like in practice

Any ibogaine provider who skips cardiac screening is not operating safely. Not offering a more accessible programme. Not cutting unnecessary overhead. Not operating safely. The EKG identifies pre-existing QT prolongation before ceremony. That identification is the difference between a ceremony and a fatality in the subset of people whose baseline QTc puts them at serious risk. Providers who skip it are removing the mechanism that identifies those people before they experience the ceremony rather than during it.

In a properly structured ibogaine programme, the following are not optional:

A physician physically present on-site throughout the 12–24 hour active experience. Not available by phone. Not on call. Present, in the room, for the full duration.
Continuous cardiac ECG monitoring running throughout the active experience. Real-time identification of any arrhythmia that develops. Not a single reading at the start. Continuous monitoring.
Emergency response capability on-site. The equipment and trained personnel to respond if something does occur. The monitoring catches problems early. The response capability handles them.
An on-site medical professional who has reviewed the pre-ceremony EKG and blood results and whose determination of candidacy decides whether ceremony proceeds. Not a facilitator who received a summary. The physician who will be present for the ceremony.

The cost of the on-site physician is a significant portion of the $2,000–$5,000 CAD cost of iboga ceremony at Transcend. Qualified physicians' time is expensive because it is genuinely skilled. Providers offering substantially lower prices are almost always removing this infrastructure — not finding efficiencies, not being generous. What they are removing is the safety component that makes the ceremony survivable for the people who would otherwise not survive it.

For more on what a complete ibogaine therapy programme in Canada includes, there is a separate article covering the full structure from intake through the integration period.

The peer-reviewed pharmacology literature on ibogaine consistently identifies cardiac monitoring and pre-ceremony cardiovascular assessment as the clinical requirements that determine whether the compound is administered safely. This is not a contested point in the medical literature. It is the consensus position of every researcher who has studied this compound seriously.

Is this right for you?

If you have read this far, you are asking a real question rather than looking for reassurance that ibogaine is fine for everyone. It is not fine for everyone. For the right person — cardiovascular profile intact, contraindications absent, screening completed — ibogaine ceremony under physician supervision with continuous ECG monitoring is a medically manageable procedure with a documented evidence base for conditions that conventional treatment has not resolved.

For the wrong person — unscreened, with pre-existing QT prolongation, taking contraindicated medications — it is a different situation entirely. The screening is what determines which category you are in.

The next step is not a ceremony date. It is a screening conversation. That conversation is how candidacy is established — specifically for your cardiovascular situation, your medication history, and your current conditions. We respond to every application personally within 2–3 business days.

Apply for ceremony →

Frequently asked questions →

What ceremony involves →

Integration support →